THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action to be taken, you should consult your licensed securities dealer or registered institution in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in Concord Healthcare Group Co., Ltd., you should at once hand this circular, together with the accompanying proxy form, to the purchaser or transferee or to the bank, licensed securities dealer or registered institution in securities or other agent through whom the sale or transfer was effected for transmission to the purchaser or the transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

美中嘉和
CONCORD MEDICAL

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

(1) REPORT OF THE DIRECTORS FOR 2025;
(2) 2025 ANNUAL REPORT;
(3) REMUNERATION OF DIRECTORS FOR 2025;
(4) RE-APPOINTMENT OF AUDITOR FOR 2026;
(5) PROPOSED REMUNERATION OF DIRECTORS FOR 2026;
(6) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES TO THE BOARD;
(7) GENERAL MANDATE TO REPURCHASE SHARES TO THE BOARD;
(8) ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT FOR 2025;
(9) NO PAYMENT OF FINAL DIVIDEND;
(10) ANNUAL RESULTS ANNOUNCEMENT FOR 2025;
(11) APPOINTMENT OF AN EXECUTIVE DIRECTOR; AND
(12) PROPOSED REMUNERATION OF A NEWLY APPOINTED DIRECTOR FOR 2026
AND
NOTICE OF ANNUAL GENERAL MEETING

A letter from the Board is set out on pages 4 to 15 of this circular.

A notice convening the AGM to be held at A1, 26th Floor, Hanwei Building East Area, No. 7 Guanghua Road, Chaoyang District, Beijing, PRC on Monday, May 11, 2026 at 9:30 a.m. is set out on pages 22 to 26 of this circular. A form of proxy for use at the AGM is also enclosed. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.concordmedical.com).

Whether or not you are able to attend the AGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for the holding of AGM (i.e. before 9:30 a.m. on Sunday, May 10, 2026) or any adjournment thereof. Completion and return of the form of proxy will not preclude shareholders from attending and voting in person at the AGM (or any adjournment thereof) if they so wish. In such event, the form of proxy shall be deemed to be revoked.

April 15, 2026

CONTENTS

Page

Definitions 1

Letter from the Board 4

Appendix I – Explanatory Statement on Share Repurchase 16

Appendix II – Biographical Details of the Proposed Director Mr. Jiang Wei 20

Notice of Annual General Meeting 22

In this circular, unless the context otherwise requires, the following expressions shall have the following meanings:

"2025 Annual Report"	the annual report of the Company for the year ended December 31, 2025, which has been published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.concordmedical.com)
"AGM" or "Annual General Meeting"	the annual general meeting of the Company for the year ended December 31, 2025 to be held at A1, 26th Floor, Hanwei Building East Area, No. 7 Guanghua Road, Chaoyang District, Beijing, PRC on Monday, May 11, 2026 at 9:30 a.m. or any adjournment thereof
"Articles of Association" or "Articles"	the articles of association of the Company, as amended from time to time
"Audit Committee"	the audit committee of the Board
"Board of Directors" or "Board"	the board of directors of our Company
"China," "Mainland China" or "PRC"	the People's Republic of China, excluding, for the purposes of this Circular and for geographical reference only and except where the context requires otherwise, Hong Kong, the Macau Special Administrative Region of the PRC and Taiwan
"Company," "our Company," "we" or "us"	Concord Healthcare Group Co., Ltd. (美中嘉和醫學技術發展集團股份有限公司), a joint stock company incorporated in the PRC with limited liability on July 23, 2008, the issued H Shares of which are listed on the Main Board of the Stock Exchange (Stock Code: 2453)
"Company Law" or "PRC Company Law"	the Company Law of the PRC (中華人民共和國公司法), as amended, supplemented or otherwise modified from time to time
"Concord Medical"	Concord Medical Services Holdings Limited, a company incorporated in the Cayman Islands on November 27, 2007 and listed on the New York Stock Exchange (symbol: CCM) since December 11, 2009

"Controlling Shareholders"	has the meaning ascribed to it under the Listing Rules and unless the context otherwise requires, refers to Dr. Yang, Morgancreek Investment Holdings Limited, Concord Medical, Ascendium Group Limited, Shanghai Huifu Technology Development Co., Ltd. (上海卉馥科技發展有限公司), Concord Hospital Management Group Limited, Medstar (Shanghai) Enterprise Management Co., LTD Limited (醫學之星(上海)企業管理有限公司) (previously known as Shanghai Medstar Financial Leasing Company Limited (醫學之星(上海)融資租賃有限公司), Beijing Concord Medical Technology Co., Ltd. (北京泰和誠醫療技術有限公司), Tianjin Concord Medical Technology Co., Ltd. (天津泰和誠醫療技術有限公司) and Shanghai Xinhe Enterprise Management Center (Limited Partnership) (上海信荷企業管理中心(有限合夥))
"Director(s)"	the director(s) of our Company
"Domestic Share(s)"	ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are not listed on the Stock Exchange
"Domestic Share Shareholder(s)"	holder(s) of Domestic Share(s)
"H Share(s)"	ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, which is/are to be subscribed for and traded in HK dollars and listed on the Stock Exchange
"H Share Shareholder(s)"	holder(s) of H Shares
"Issue Mandate"	subject to the conditions set out in the proposed resolution approving the Issue Mandate at the AGM, the general mandate to be given to the Board to, among others, exercise the power of the Company to allot, issue and/or deal with up to a maximum of 20% of the total number of Shares in issue as at the date of passing the relevant resolution at the AGM. Details of the Issue Mandate are set out in special resolution numbered 6 in the notice convening the AGM dated April 15, 2026

"Latest Practicable Date"	April 14, 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained in this circular
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
"Nomination Committee"	the nomination committee of the Board
"Remuneration and Appraisal Committee"	the remuneration and appraisal committee of the Board
"Renminbi" or "RMB"	the lawful currency of the PRC
"Repurchase Mandate"	subject to the conditions set out in the proposed resolution approving the Repurchase Mandate at the AGM, the general mandate to be given to the Board to exercise the power of the Company to repurchase H Shares of up to a maximum of 10% of the total number of H Shares in issue as at the date of passing such resolution. Details of the Repurchase Mandate are set out in special resolution numbered 7 in the notice convening the AGM dated April 15, 2026
"SAFE"	the State Administration of Foreign Exchange of the PRC (中華人民共和國國家外匯管理局)
"Share(s)"	ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, comprising Domestic Shares and H Shares
"Shareholder(s)"	holder(s) of our Share(s)
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Takeovers Code"	The Code on Takeovers and Mergers approved by the Securities and Futures Commission as amended from time to time
"US$"	U.S. dollar(s)
"%"	Percent

CONCORD HEALTHCARE GROUP CO., LTD.
美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2453)

Executive Directors:
Dr. YANG Jianyu *(Chairman)*
Ms. FU Xiao
Mr. CHANG Liang

Non-Executive Directors:
Mr. WANG Lei
Mr. SONG Qingbao
Mr. SHI Botao

Independent Non-Executive Directors:
Ms. LI Xuemei
Mr. SUN Yansheng
Mr. NG Kwok Yin

Registered office:
Room B311, 3rd Floor, Building 7
No. 48, Zhongguancun South Road
Haidian District
Beijing, PRC

Headquarters and Principal Place of Business in the PRC:
Room 26A1-26A5, East Tower,
Hanwei Building
No. 7 Guanghua Road
Chaoyang District
Beijing, PRC

Principal Place of Business in Hong Kong:
Room 1701, 9 Chong Yip Street
Kwun Tong, Kowloon
Hong Kong

April 15, 2026

To the Shareholders

Dear Sir/Madam,

(1) REPORT OF THE DIRECTORS FOR 2025;
(2) 2025 ANNUAL REPORT;
(3) REMUNERATION OF DIRECTORS FOR 2025;
(4) RE-APPOINTMENT OF AUDITOR FOR 2026;
(5) PROPOSED REMUNERATION OF DIRECTORS FOR 2026;
(6) GENERAL MANDATE TO ISSUE ADDITIONAL SHARES TO THE BOARD;
(7) GENERAL MANDATE TO REPURCHASE SHARES TO THE BOARD;
(8) ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT FOR 2025;
(9) NO PAYMENT OF FINAL DIVIDEND;
(10) ANNUAL RESULTS ANNOUNCEMENT FOR 2025;
(11) APPOINTMENT OF AN EXECUTIVE DIRECTOR; AND
(12) PROPOSED REMUNERATION OF A NEWLY APPOINTED DIRECTOR FOR 2026
AND
NOTICE OF ANNUAL GENERAL MEETING

I. INTRODUCTION

The AGM of the Company will be held at 9:30 a.m. on Monday, May 11, 2026.

The purpose of this circular is to provide you with all the information reasonably necessary to enable you to make an informed decision on voting in respect of the relevant resolutions at the AGM.

The resolutions to be proposed at the AGM for the Shareholders' approval include: (1) resolution to consider and approve the report of the Directors for 2025; (2) resolution to consider and approve the 2025 Annual Report; (3) resolution to consider and approve the remuneration of Directors for 2025; (4) resolution to consider and approve the re-appointment of auditor for 2026; (5) resolution to consider and approve the proposed remuneration of Directors for 2026; (6) resolution to consider and approve the granting of general mandate to issue additional Shares to the Board; (7) resolution to consider and approve the general mandate to repurchase Shares to the Board; (8) resolution to consider and approve the Environmental, Social and Governance Report for 2025; (9) resolution to consider and approve no payment of final dividend; (10) resolution to consider and approve the Annual Results Announcement for 2025; (11) resolution to consider and approve the appointment of an executive Director; and (12) resolution to consider and approve the proposed remuneration of a newly appointed Director for 2026.

Except for resolutions numbered (6) and (7), all of the other resolutions are ordinary resolutions. Resolutions numbered (6) and (7) are special resolutions.

II. DETAILS OF RESOLUTIONS

(1) To consider and approve the report of the Directors for 2025

The full text of the report of the Directors for 2025 is set out in the section headed "Report of the Directors" in the 2025 Annual Report.

The report of the Directors for 2025 will be proposed at the AGM for consideration and approval.

(2) To consider and approve the 2025 Annual Report

The 2025 Annual Report will be proposed at the AGM for consideration and approval.

(3) To consider and approve the remuneration of Directors for 2025

The remuneration of Directors for the year ended December 31, 2025 is follows:

For the year ended December 31, 2025	Fees	Salaries, allowances and benefits in kind	Discretionary bonuses	Retirement scheme contributions	Total
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*	*RMB'000*
Executive Directors					
Dr. YANG Jianyu	–	1,006	36	195	1,236
Ms. FU Xiao	–	1,369	227	–	1,596
Mr. CHANG Liang	–	841	69	148	1,057
Non-executive Directors					
Mr. WANG Lei	–	–	–	–	–
Mr. CHEN Hongzhang (resigned as a Non-executive Director on May 27, 2025)	–	–	–	–	–
Mr. SONG Qingbao (appointed as a Non-executive Director on May 27, 2025)	–	–	–	–	–
Mr. SHI Botao	–	–	–	–	–
Independent Non-executive Directors					
Ms. LI Xuemei	200	–	–	–	200
Mr. SUN Yansheng	200	–	–	–	200
Mr. NG Kwok Yin	200	–	–	–	200
	600	3,215	332	342	4,489

The abovementioned executive Directors have not received compensation in any of the shareholder entities or other related parties.

The remuneration of each of the non-executive Directors, namely Mr. WANG Lei, Mr. CHEN Hongzhang, Mr. SONG Qingbao, and Mr. SHI Botao, was nil for the year ended December 31, 2025.

The remuneration of each of the independent non-executive Directors, namely Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin, was RMB200,000 (pre-tax) for the year ended December 31, 2025.

The remuneration of Directors for 2025 will be proposed at the AGM for approval.

(4) To consider and approve the re-appointment of auditor

The Board proposed the re-appointment of BDO Limited as the Company's auditor for the year ending December 31, 2026, and will submit to the AGM the aforementioned re-appointment proposal for approval and to authorize the Audit Committee to determine the remuneration of the auditor for the year ending December 31, 2026.

(5) To consider and approve the proposed remuneration of Directors for 2026

In accordance with the Company Law, the Articles of Association and the Company's remuneration policy and other requirements, the Remuneration and Appraisal Committee has comprehensively taken into account the Company's actual circumstance and the remuneration level of directors in the same industry and other comparable companies. Details of the proposed remuneration for the members of the Board for the year ending December 31, 2026 are set out below:

Name	**Position**	**Proposed annual remuneration (pre-tax)** *RMB'000*	**Performance assessment**
Dr. Yang Jianyu	Chairman of the Board and executive Director	1,500	Entitled to commissions determined on the extent of meeting the targets regarding revenue and profit
Ms. FU Xiao	Executive Director	720	Entitled to commissions determined on the extent of meeting the targets regarding revenue and profit
Mr. CHANG Liang	Executive Director and executive president	1,250	Entitled to commissions determined on the extent of meeting the targets regarding revenue and profit

The proposed remuneration of each of the non-executive Directors is nil for the year ending December 31, 2026.

The proposed remuneration of each of the independent non-executive Directors is RMB200,000 (pre-tax) for the year ending December 31, 2026.

The proposed remuneration of the members of the Board for the year ending December 31, 2026 will be presented at the AGM for consideration and approval.

(6) To consider and approve the granting of general mandate to issue additional Shares to the Board

In order to satisfy the needs of business development and further increase the capital strength and comprehensive capability of the Company, the Board intends to propose the Shareholders to, on the premise of compliance with the securities regulatory requirements of the place where the Shares of the Company are listed or other applicable laws and regulations, authorize the Board and its authorized persons, on a general basis, to decide to separately or concurrently allot, issue and/or deal with new Shares not more than 20% of the total number of the Shares in issue of the Company as at the date of this resolution being considered and approved at the AGM.

The details or such general mandate are set out in special resolution numbered (6) in the notice convening the AGM.

As at the Latest Practicable Date, there were 313,874,624 Domestic Shares and 469,787,392 H Shares in issue. Subject to the passing of the proposed special resolution approving the grant of the Issue Mandate to the Board and on the basis that no Shares will be issued by the Company prior to the AGM, a maximum of 156,732,403 Shares (including both Domestic Shares and H Shares), can be separately or concurrently allotted, issued and/or dealt with by the Board pursuant to the Issue Mandate to be granted by the Shareholders. The Issue Mandate will expire upon the earliest of:

(a) the passing of the relevant resolution by the next annual general meeting of the Company;

(b) the expiration of a 12-month period following the passing of the relevant resolution at the AGM; or

(c) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the Shareholders in a general meeting.

A special resolution will be proposed at the AGM in relation to the granting of the Issue Mandate to the Directors to issue, allot and/or deal with additional Shares, details of which are set out in special resolution numbered (6) of the notice of the AGM.

(7) To consider and approve the granting of general mandate to repurchase Shares to the Board

According to the Company Law and the Articles of Association, the Company purchases its own shares under any of the following circumstances, it may, in accordance with the Articles of association or the authorization of the shareholders' general meeting, make a resolution at a board meeting attended by more than two-thirds of the directors: (I) using the shares for

employee stock ownership plan or equity incentive; (II) using the shares for conversion of convertible corporate bonds issued by the Company; and (III) when it is necessary for the Company to protect the company value and the shareholders' equity.

Where the Company acquires its shares due to the above circumstances, the acquisition shall be conducted through a public and centralized trading method.

After the Company acquires its shares in accordance with the above regulations, the cumulative Shares repurchased by the Company shall not exceed 10% of the Shares in issue and shall be transferred or deregistered within three years.

The Listing Rules permit shareholders of a joint stock limited company duly incorporated in the PRC to grant a general mandate to its directors to repurchase H shares of such company that are listed on the Stock Exchange. Such mandate is required to be given by way of an ordinary resolution passed by shareholders in general meeting.

As the H Shares are traded on the Stock Exchange in Hong Kong dollars, the amount payable by the Company upon any repurchase of its H Shares will, therefore, be paid in Hong Kong dollars, the approvals of SAFE and other relevant government authorities are required for any repurchase of H Shares.

In accordance with the requirements of Article 180 of the Articles of Association applicable to capital reduction, the Company is required to prepare a balance sheet and a schedule of assets upon the reduction of its registered capital. The Company shall notify its creditors of the passing of such special resolution and the reduction of the registered capital of the Company that would occur should the Company decide to exercise the Repurchase Mandate. Such notification should be given in writing to the Company's creditors and be published by way of an announcement within 10 days and 30 days after the passing of such special resolution, respectively. Creditors then have a period of up to 30 days after receipt of the Company's written notification or if no such notification has been received, up to 45 days after the publication of the announcement to require the Company to repay amounts due to them or to provide guarantees thereof.

The registered capital of the Company after the capital reduction shall not be lower than the statutory minimum level required by laws.

In order to ensure flexibility and discretion to the Directors in the event that it becomes desirable to repurchase any H Shares, approval is proposed to be sought from the Shareholders for the Repurchase Mandate. In accordance with the legal and regulatory requirements described above, the Directors have given notices to convene the AGM. At the AGM, a special resolution will be proposed to grant to the Directors the Repurchase Mandate, i.e. a conditional general mandate to repurchase H Shares up to a maximum of 10% of the total number of H Shares in issue as at the date of passing such special resolution on the Stock Exchange.

The Repurchase Mandate will be conditional upon:

(a) the passing of the special resolution approving the grant of the Repurchase Mandate at the AGM;

(b) the obtaining of the approvals of the relevant regulatory authorities as required by the laws, rules and regulations; and

(c) the compliance with the requirements by laws, regulations and the Articles of Association, including but not limited to Chapter 10 of the Listing Rules, and the Company not being required by any of its creditors to repay or to provide guarantee in respect of any amount due to any of them (or if the Company is so required by any of its creditors, the Company having, in its absolute discretion, repaid or provided guarantee in respect of such amount).

If the Company determines to repay any amount to any of its creditors in the circumstances described under condition (c) above, it expects to do so out of its internal generated fund. If the conditions are not fulfilled, the Repurchase Mandate will not be exercised by the Directors.

The Repurchase Mandate, if approved at the AGM, would expire on the earliest:

(a) the passing of the relevant resolution by the next annual general meeting of the Company; or

(b) the expiration of a 12-month period following the passing of this resolution at the AGM; or

(c) the date on which the authority set out in this resolution is revoked or varied by special resolutions of the Shareholders in a general meeting.

An explanatory statement containing all relevant information relating to the Repurchase Mandate is set out in Appendix I to this circular. The information in the explanatory statement is to provide you with the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the resolution to grant to the Directors the Repurchase Mandate.

A special resolution will be proposed at the AGM in relation to the grant of the Repurchase Mandate of H Shares to the Directors, details of which are set out in special resolution numbered (7) of the notice of the AGM.

(8) To consider and approve the 2025 Environmental, Social and Governance Report

The 2025 Environmental, Social and Governance Report will be proposed at the AGM for consideration and approval.

(9) To consider and approve no payment of final dividend

Board has recommended not to pay any final dividend for the year ended December 31, 2025 on March 27, 2026.

(10) To consider and approve the 2025 Annual Results Announcement and related authorisations

Based on the business operations of the Company for the year ended December 31, 2025, the Company has prepared the draft annual results announcement for the year ended December 31, 2025, together with related documents, including the independent auditor's report and the 2025 Annual Report.

At the AGM, Shareholders will be requested to consider and approve the annual results announcement of the Company for the year ended December 31, 2025 and to authorise:

(a) any one executive Director or the company secretary to make such revisions, variations or amendments (if any) to the annual results announcement and related documents as he or she may consider necessary or appropriate and to finalise the same;

(b) the chairman of the Board, Dr. Yang Jianyu, or any one executive Director to sign any documents in connection with the annual results of the Company for the year ended December 31, 2025;

(c) the chairman of the Board, Dr. Yang Jianyu, to sign, for and on behalf of the Company, the Directors' Report contained in the annual report of the Company; and

(d) any one Director or the company secretary, for and on behalf of the Board, to publish the annual results announcement (in both Chinese and English) and the annual report (in both Chinese and English) on the websites of The Stock Exchange of Hong Kong Limited and the Company in accordance with the Listing Rules, and to approve the final version of the annual report for bulk printing and the dispatch of printed copies to Shareholders, and to do all such other acts as may be necessary, desirable or expedient in connection therewith.

The annual results announcement for the year ended December 31, 2025 will be proposed at the AGM for consideration and approval.

(11) To consider and approve the appointment of an executive Director

Ms. FU Xiao, an executive Director of the Company, has tendered her resignation as an executive Director as she has reached the statutory retirement age. Following her resignation, she will continue to support the Company as a consultant.

In order to ensure the effective and orderly operation of the Board, and in accordance with the PRC Company Law and the Articles of Association, the Board has nominated Mr. JIANG Wei for appointment as an executive Director of the fourth session of the Board. Subject to approval by the Shareholders at the AGM, Mr. JIANG Wei will hold office from the date of the AGM until the expiry of the term of the fourth session of the Board.

Upon approval of his appointment, the Company will enter into a service agreement with Mr. JIANG Wei. His remuneration will be determined in accordance with the remuneration policy approved by the Shareholders at the AGM and will be disclosed in the relevant annual report of the Company.

Following the above changes, the composition of the fourth session of the Board will comprise the existing executive Directors, non-executive Directors and independent non-executive Directors as set out in this circular.

To ensure continuity of the Board's work, Ms. FU Xiao will continue to perform her duties in accordance with applicable laws and the Articles of Association until the new appointment takes effect.

Biographical details of the proposed director, Mr. JIANG Wei, are set out in Appendix II to this circular.

An ordinary resolution will be proposed at the AGM to consider and approve the above matters.

(12) To consider and approve the proposed remuneration of a newly appointed Director for 2026

In accordance with the Company Law, the Articles of Association and the Company's remuneration policy and other relevant requirements, the Remuneration and Appraisal Committee has comprehensively taken into account the Company's actual circumstances as well as the remuneration levels of directors in the same industry and other comparable companies.

Details of the proposed remuneration of a newly appointed Director of the Company for the year ending 31 December 2026 are set out below:

Name	Position	Proposed annual remuneration (pre-tax) *RMB'000*	Performance assessment
Mr. JIANG Wei	Executive Director, General Manager and President	1,800	Entitled to commissions determined on the extent of meeting the targets regarding revenue and profit

The proposed remuneration of Mr. Jiang Wei, being a Director of the Company for the year ending 31 December 2026 will be presented at the AGM for consideration and approval.

III. CLOSURE OF REGISTER OF MEMBERS

For determining the entitlement to attend and vote at the AGM, the record date will be May 11, 2026 and the register of members of H Shares of the Company will be closed from May 6, 2026 to May 11, 2026, both days inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the AGM, all transfer documents of H shares accompanied by the relevant shares certificates must be lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong before 4:30 p.m. on May 5, 2026.

IV. NOTICE OF ANNUAL GENERAL MEETING

Set out on pages 22 to 26 of this circular is the notice of the AGM at which, inter alia, all the ordinary resolutions and special resolutions will be proposed to the Shareholders to consider and approve ascribed in details in "– II. Details of Resolutions" section in this letter.

V. FORM OF PROXY

A form of proxy is enclosed for use at the AGM. Such form of proxy is also published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.concordmedical.com). Whether or not you intend to attend the AGM, you are requested to complete the form of proxy in accordance with the instructions printed thereon and return it to the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong as soon as possible but in any event not less than 24 hours before the time appointed for holding the AGM (i.e. before 9:30 a.m. on Sunday, May 10, 2026) or any adjournment thereof.

Completion and return of the form of proxy will not preclude Shareholders from attending and voting in person at the AGM or any adjournment thereof if they so wish. In such event, the form of proxy shall be deemed to be revoked.

VI. VOTING BY POLLS

As at the Latest Practicable Date, to the best of the knowledge, information and belief of the Directors after having made all reasonable inquiries, no Shareholder will be required to abstain from voting at the AGM.

Pursuant to Rule 13.39(4) of the Listing Rules, at any general meeting a resolution put to the vote of the meeting is to be decided by way of a poll, except where the chairman, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands. Accordingly, the resolution set out in the notice of AGM will be decided by way of a poll.

On a poll, every Shareholder present in person or by proxy or, in the case of a Shareholder being a corporation, by its duly authorized representative shall have one vote for every fully paid Share of which he is the holder. A Shareholder entitled to more than one vote needs not use all his votes or cast all the votes he uses in the same way.

An announcement on the poll results will be published by the Company after the AGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

VII. RECOMMENDATIONS

The Board considers that each of the matters to be put to the Shareholders for voting at the AGM are in the interests of the Company and its shareholders as a whole. Accordingly, the Board recommends the Shareholders to vote in favor of all the resolutions at the AGM as set forth in the notice of the AGM.

VIII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purposes of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

IX. ADDITIONAL INFORMATION

Your attention is drawn to the additional information set out in the appendices to this circular.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman of the Board and Executive Director

The following is an explanatory statement required by the Listing Rules to provide the Shareholders with requisite information reasonably necessary for them to make an informed decision on whether to vote for or against the special resolution to be proposed at the AGM in relation to the granting of the Repurchase Mandate.

1. SHARE CAPITAL

As at the Latest Practicable Date, the issued share capital of the Company comprised 313,874,624 Domestic Shares with a nominal value of RMB1.00 each and 469,787,392 H Shares with a nominal value of RMB1.00 each.

2. REASONS FOR REPURCHASE OF H SHARES

The Directors believe that it is in the best interests of the Company and its Shareholders for the Directors to seek a mandate from the Shareholders to enable the Company to repurchase H Shares in the market. Such repurchase may, depending on the market conditions and funding arrangement at the time, lead to an enhancement of the net asset value of the Company and/or its earnings per Share and will only be made when the Directors believe that such a repurchase will benefit the Company and its Shareholders taken as a whole.

3. EXERCISE OF THE REPURCHASE MANDATE

Subject to the passing of the relevant special resolution set out in the notice of the AGM, the Directors will be granted the Repurchase Mandate until the end of the Relevant Period (as defined in the notice of the AGM). In addition, the exercise of the Repurchase Mandate may be subject to the approvals of the relevant PRC regulatory authorities as required by the laws, rules and regulations of the PRC being obtained and to the compliance with the requirements by laws, regulations and the Articles of Association, including but not limited to Chapter 10 of the Listing Rules, and the Company not being required by any of its creditors to repay or to provide guarantee in respect of any amount due to any of them (or if the Company is so required by any of its creditors, the Company having, in its absolute discretion, repaid or provided guarantee in respect of such amount).

As at the Latest Practicable Date, assuming the Repurchase Mandate is approved at the AGM, the exercise in full of the Repurchase Mandate would result in up to 46,978,739 H Shares (assuming there is no issue of additional H Shares from the Latest Practicable Date up to the date of the AGM) being repurchased by the Company during the Relevant Period (as defined in the notice of the AGM).

4. FUNDING OF REPURCHASE OF H SHARES

The Company may only apply funds legally available for share repurchase in accordance with its Articles of Association, the laws of PRC and/or any other applicable laws, as the case may be.

In accordance with the requirements of PRC applicable laws or administrative regulations, and may be subject to the approval of relevant authority, the Company is entitled by its Articles of Association to purchase its H Shares. The Company may not repurchase H Shares on the Stock Exchange for a consideration other than cash or for settlement otherwise than in accordance with the trading rules of the Stock Exchange from time to time.

Based on the financial position disclosed in the recently published audited accounts for the year ended December 31, 2025, the Directors consider that there will not be any material adverse impact on the working capital or gearing position of the Company in the event that the Repurchase Mandate is to be exercised in full at any time during the proposed repurchase period. The number of H Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Directors at the relevant time having regarded to the circumstances then prevailing and in the best interests of the Company.

5. STATUS OF REPURCHASED H SHARES

All the H Shares repurchased by the Company will be cancelled and the relevant share certificates will be cancelled and destroyed.

6. MARKET PRICES OF H SHARES

The highest and lowest prices per H Share at which H Shares have traded on the Stock Exchange in each of the previous twelve months were as follows:

Month	**Highest**	**Lowest**
	HK$	*HK$*
2025		
April	8.96	5.77
May	7.78	5.93
June	7.91	5.25
July	7.49	5.55
August	6.38	5.27
September	5.35	2.90
October	3.28	2.50
November	2.51	1.77
December	2.15	1.67
2026		
January	1.98	1.52
February	1.83	1.28
March	1.54	1.02
April (up to the Latest Practicable Date)	1.42	1.15

7. GENERAL INFORMATION

The Directors consider that there would not be a material adverse impact on the working capital or on the gearing position of the Company in the event that the Repurchase Mandate is exercised in full at any time during the proposed repurchase period (as compared with the position disclosed in the latest published audited accounts of the Company for the year ended December 31, 2025). However, the Directors do not propose to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements of the Company or the gearing levels of the Company. The number of H Shares to be repurchased on any occasion and the price and other terms upon which the same are repurchased will be decided by the Board at the relevant time having regarded to the circumstances then prevailing, in the best interests of the Company.

The Directors have undertaken to the Stock Exchange that, so far as the same may be applicable, they will exercise the powers of the Company to make repurchases under the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and the applicable laws, rules and regulations of the PRC. Neither this explanatory statement nor the proposed share repurchase has unusual features.

To the best of the knowledge of the Directors having made all reasonable enquiries, none of the Directors or any of their respective close associates (as defined in the Listing Rules) have any present intention to sell any H Shares to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders. The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H Shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the granting of the Repurchase Mandate is approved by the Shareholders.

8. EFFECT OF THE TAKEOVERS CODE

If as a result of a repurchase of H Shares pursuant to the Repurchase Mandate, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of Rule 32 of the Takeovers Code. Accordingly, a Shareholder or a group of Shareholders acting in concert (within the meaning under the Takeovers Code), depending on the level of increase in the Shareholder's interest, could obtain or consolidate control of the Company and thereby become obliged to make a mandatory offer in accordance with Rule 26 of the Takeovers Code.

As at the Latest Practicable Date, our Controlling Shareholders are entitled to exercise approximately 32.68% of the voting rights of the Company. In the event that the Directors exercise the proposed Repurchase Mandate in full, our Controlling Shareholders would be entitled to exercise approximately 34.76% of the voting rights of the Company.

The Directors do not propose to exercise the Repurchase Mandate to such an extent as would, in the circumstances, give rise to an obligation to make a mandatory offer in accordance with Rules 26 and 32 of the Takeovers Code and/or result in the aggregate number of H Shares held by the public shareholders falling below the prescribed minimum percentage required by the Stock Exchange. The Directors are not aware of any consequences which will arise under the Takeovers Code and/or any similar applicable law, as a result of any purchases to be made under the Repurchase Mandate. The Company has not been notified by any core connected persons (as defined in the Listing Rules) of the Company that they have a present intention to sell any H shares to the Company, or that they have undertaken not to sell any H Shares held by them to the Company in the event that the Repurchase Mandate is approved and the conditions (if any) to which the Repurchase Mandate are fulfilled.

9. SHARE REPURCHASE MADE BY THE COMPANY

During the six months preceding the Latest Practicable Date, the Company had not repurchased any of its H Shares (whether on the Stock Exchange or otherwise).

Biographical details of the proposed Directors of the fourth session of the Board are as follows:

Mr. Jiang, aged 45, is the President of the Company. Mr. Jiang joined the Group in 2020. From June 2020 to date, Mr. Jiang has been serving as the chief executive officer and a director of Beijing Healthingkon Technology Co., Ltd. (北京和信康科技有限公司), the principal AI business entity of the Group, and has successively served as the chairman of Shanghai Concord Medical Diagnostic Imaging Limited (上海美中嘉和醫學影像診斷有限公司), a director of Guangzhou Concord Cancer Center Co., Ltd. (廣州泰和腫瘤醫院有限公司), a director of Shanghai Concord Medical Cancer Hospital Limited (上海泰和誠腫瘤醫院有限公司), and the chief financial officer of Concord Medical Services Holdings Limited.

Prior to joining the Group, he worked at Ernst & Young from July 2003 to June 2007. From July 2007 to May 2020, he was employed by China International Capital Corporation Limited, during which he served in various departments, including the Planning and Analysis Department, the Investment Banking Department and CICC Capital.

Mr. Jiang obtained his Bachelor of Finance degree from the School of Economics of Peking University in 2003 and an MBA degree from Guanghua School of Management, Peking University in July 2012.

Mr. Jiang as an executive Director of the Company and the President, will focus on the principal business of oncology diagnosis and treatment in the future. He will further integrate the Group's strengths in clinical capabilities and data resources with AI technologies, continue to lead the team in deepening its presence in the field of AI-enabled oncology diagnosis and treatment, and actively expand overseas businesses, thereby consolidating the Group's leading position in the industry.

Mr. Jiang has confirmed that, apart from the disclosures made above: (i) he does not hold any other positions in the Company or any of its subsidiaries, nor has he served as a director of any other listed companies in the past three years; (ii) he has no relationship with any other directors, senior management, or substantial shareholders of the Company or any of its subsidiaries; and (iii) as of the latest practicable date, he does not have any interests in the shares of the Company as defined in Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Mr. Jiang also confirmed that there is no other information regarding his appointment that needs to be disclosed in accordance with Rules 13.51(2)(h) to (w) of the Hong Kong Listing Rules, and there are no other matters pertaining to his appointment that require shareholders' attention.

As an executive director of the fourth session of the board of directors of the Company, Mr. Jiang's term of office will commence from the date of approval of his appointment at the annual general meeting and end on the date of expiration of the term of office of the fourth session of the board of directors. The board of directors authorizes the management of the Company to sign a director service contract with Mr. Jiang upon his formal appointment as an executive director of the Company and handle relevant filing matters. After serving as an executive director of the Company, Mr. Jiang will receive a salary of RMB1,800,000 for the year ending December 31, 2026.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.

CONCORD HEALTHCARE GROUP CO., LTD.

美中嘉和醫學技術發展集團股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2453)

NOTICE OF ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN that an annual general meeting (the "AGM") of Concord Healthcare Group Co., Ltd. (the "Company") for the year ended December 31, 2025 will be held at A1, 26th Floor, Hanwei Building East Area, No. 7 Guanghua Road, Chaoyang District, Beijing, PRC on Monday, May 11, 2026 at 9:30 a.m. to consider and, if thought fit, to pass the following resolutions. Unless otherwise defined, capitalized terms herein shall have the same meaning as defined in the circular (the "Circular") of the Company dated April 15, 2026.

ORDINARY RESOLUTIONS

By way of ordinary resolutions, to consider and, if thought fit, pass with or without amendments, the following resolutions as ordinary resolutions:

1. To consider and approve the report of the Directors for 2025

2. To consider and approve the 2025 Annual Report

3. To consider and approve the remuneration of Directors for 2025

4. To consider and approve the re-appointment of auditor

5. To consider and approve the proposed remuneration of Directors for 2026

8. To consider and approve the 2025 Environmental, Social and Governance Report

9. To consider and approve no payment of final dividend

10. To consider and approve the 2025 Annual Results Announcement and related authorisations

11. To consider and approve the appointment of an executive Director

12. To consider and approve the proposed remuneration of a newly appointed Director for 2026

SPECIAL RESOLUTIONS

By way of special resolutions, to consider and, if thought fit, pass with or without amendments, the following resolutions as special resolutions:

6. To consider and approve the granting of general mandate to issue additional Shares to the Board

   (a) the Board be and is hereby granted an unconditional general mandate to separately or concurrently issue, allot and/or deal with additional Domestic and/or H Shares in the share capital of the Company and to make any proposals, enter into any agreement or grant any conversion rights in respect thereof, subject to the following terms:

      a. such mandate shall not extend beyond the Relevant Period save that the Board may during the Relevant Period make any proposals, enter into any agreement or grant any conversion rights which might require the exercise of such powers after the end of the Relevant Period;

      b. the total number of new Shares (including both Domestic and H Shares) to be allotted or agreed conditionally or unconditionally to be allotted and issued (whether or not by way of an exercise of conversion rights or by any other means) by the Board shall not exceed 20% of the total number of Shares in issue as at the date of passing this resolution, being 156,732,403 Shares; and

      c. the Board will only exercise its power under such mandate in accordance with the Company Law of the PRC and the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (including but not limited to Rules 13.36(6) and 13.36(7)) and only if all necessary approvals from the China Securities Regulatory Commission and/or other relevant PRC government authorities are obtained.

   (b) for the purpose of this resolution:

"**Domestic Share(s)**" means ordinary share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which is/are not listed on the Stock Exchange;

"**H Share(s)**" means ordinary share(s) in the share capital of our Company with a nominal value of RMB1.00 each, which is/are to be subscribed for and traded in HK dollars and listed on the Stock Exchange;

"**Relevant Period**" means the period from the passing of this resolution until the earliest of the three periods below:

(i) the passing of the relevant resolution by the next annual general meeting of the Company;

(ii) the expiration of a 12-month period following the passing of this resolution at the AGM; or

(iii) the date on which the authority set out in this resolution is revoked or varied by a special resolution of the Shareholders of the Company in a general meeting.

(c) contingent on the Board's resolving to issue Shares pursuant to paragraph (a) of this resolution, the Board be and is hereby authorized to approve, execute and do or procure to be executed and done, all such documents, deeds and things as it may consider relevant in connection with the issue of such new Shares, including, but not limited to, determining the time and place of issue, making all necessary applications to the relevant authorities and entering into an underwriting agreement (or any other agreement), to determine the use of proceeds and to make all necessary filings and registrations with the relevant PRC, Hong Kong and other authorities, and to make such amendments to the Articles of Association as it thinks fit so as to reflect the increase in registered capital of the Company and to reflect the new share capital structure of the Company under the intended allotment and issue of the Shares of the Company pursuant to the resolution under paragraph (a) of this resolution.

7. To consider and approve the granting of general mandate to repurchase Shares to the Board

(a) subject to paragraphs (b) and (c) below, the Board be and is hereby authorized to exercise all the powers of the Company to repurchase the H Shares (as defined in paragraph 15(b) above) in issue of the Company on the Stock Exchange during the Relevant Period (as defined in paragraph 15(b) above), subject to and in accordance with all applicable laws, rules and regulations and/or requirements of the PRC, the Stock Exchange or any other governmental or regulatory bodies.

(b) the total number of H Shares of the Company authorized to be repurchased subject to the approval in paragraph (a) above during the Relevant Period shall not exceed 10% of the total number of the H Shares in issue of the Company as at the date of the passing of this resolution.

(c) the approval in paragraph (a) above shall be conditional upon:

a. the passing of a special resolution at the AGM of the Company to be held on May 11, 2026;

b. the approval of the relevant regulatory authorities as may be required by laws, rules and regulations being obtained by the Company; and

c. the compliance with the requirements by laws, regulations and the Articles of Association, including but not limited to Chapter 10 of the Listing Rules, and the Company not being required by any of its creditors to repay or to provide guarantee in respect of any amount due to any of them (or if the Company is so required by any of its creditors, the Company having, in its absolute discretion, repaid or provided guarantee in respect of such amount).

(d) subject to approval of all relevant PRC regulatory authorities for the repurchase of such H Shares being granted, and contingent on the Board's resolving to repurchase H Shares pursuant to paragraph (a) of this resolution, the Board be and is hereby authorized to approve, execute and do or procure to be executed and done, all such documents, deeds and things as it may consider relevant in connection with the repurchase, including but not limited to:

a. make such amendments to the Articles of Association of the Company accordingly as it thinks fit so as to reduce the registered share capital of the Company and to reflect the new capital structure of the Company upon the repurchase of H Shares of the Company as contemplated in paragraph (a) above, and file the amended Articles of Association of the Company with the relevant governmental authorities of the PRC; and

b. make all necessary filing and obtain all necessary approvals, as it thinks fit, with the relevant governmental authorities.

By order of the Board
Concord Healthcare Group Co., Ltd.
YANG Jianyu
Chairman and Executive Director

Beijing, the PRC, April 15, 2026

Notes:

1. All resolutions at the AGM will be taken by poll pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "Listing Rules"). The results of the poll will be published on the websites of The Stock Exchange of Hong Kong Limited (www.hkexnews.hk) and the Company (www.concordmedical.com) in accordance with the Listing Rules.

2. For determining the entitlement to attend and vote at the AGM, the record date will be May 11, 2026 and the register of members of H Shares of the Company will be closed from May 6, 2026 to May 11, 2026, both days inclusive, during which period no transfer of H Shares will be registered. In order to be eligible to attend and vote at the AGM, all transfer documents of H shares accompanied by the relevant shares certificates must be lodged with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong before 4:30 p.m. on May 5, 2026.

3. H Share Shareholders and Domestic Share Shareholders who have the right to attend and vote at the AGM are entitled to appoint one or more proxies (whether or not a Shareholder) to attend and vote on his/her/its behalf. For those Shareholders who appoint more than one proxy, such proxies can only exercise their voting rights by way of poll.

4. In order to be valid, the proxy form must be completed and signed in accordance with the instructions printed thereon and return it to the Company's H Share Registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, as soon as possible and in any event not less than 24 hours before the time appointed for the holding of the AGM (for the H Share Shareholders); or to the business address of the Company in the PRC, at Room 26A1-26A5, East Tower, Hanwei Building, No. 7 Guanghua Road, Chaoyang District, Beijing, PRC not less than 24 hours before the time appointed for the holding of the AGM (for the Domestic Share Shareholders).

5. If a proxy is appointed to attend the AGM on behalf of a Shareholder, the proxy must produce a proxy form which is signed by the appointer or his/her agent so authorized in writing, or if the appointer is a legal person, sealed by the stamp of the legal person or signed by its director or agent so officially authorized. The proxy form shall specify the number of shares represented by the proxy of the Shareholder. Where a Shareholder appoints more than one proxy, he/she shall specify the number of shares represented by each proxy.

6. All persons who are registered holders of shares of the Company at the close of business (Hong Kong time) on May 11, 2026 will be entitled to attend and vote at the meeting.

7. References to time and dates in this notice are to Hong Kong time and dates.

8. Pursuant to Rule 13.39(4) of the Listing Rules, the resolutions set out in this notice will be decided by poll at the AGM.

As at the date of this notice, the Board comprises (i) Dr. YANG Jianyu, Ms. FU Xiao and Mr. CHANG Liang as executive Directors; (ii) Mr. WANG Lei, Mr. SONG Qingbao and Mr. SHI Botao as non-executive Directors; and (iii) Ms. LI Xuemei, Mr. SUN Yansheng and Mr. NG Kwok Yin as independent non-executive Directors.